The proto-oncogene c-fos is a major nuclear target for signal transduction pathways involved in the regulation of cell growth, differentiation, and transformation. Using the multistep skin carcinogenesis model, we have directly tested the ability of c-los-deficient mice to develop cancer. Upon treatment with a tumor promoter, c-los knockout mice carrying a v-H-ras transgene were able to develop benign tumors with similar kinetics and relative incidence as wild-type animals. However, c.fos-deficient papillomas quickly became very dry and hyperkeratinized, taking on an elongated, horny appearance. While wild-type papillomas eventually progressed into malignant tumors, c-los-deficient tumors failed to undergo malignant conversion. Experiments in which v-H-ras-expressing keratinocytes were grafted onto nude mice suggest that c-los-deficient cells have an intrinsic defect that hinders tumorigenesis. These results demonstrate that a member of the AP-1 family of transcription factors is required for the development of a malignant tumor.
Introduction
Advances in molecular biology have served to outline the multiple genetic components that are involved in the development of cancer. It is now well established that for a cell to grow aggressively within the context of the organism, proto-oncogenes must be mutated to become active growth inducers, tumor suppressor genes must be functionally lost, and the cell must be released from its own self-destruction program. Many of the important molecules in cancer development are proteins that function outside the nucleus of the cell, either assessing changes in the extracellular environment or relaying messages from sensor proteins to the control center of the cell. Because mitogens, growth factors, and tumor promoters regularly use these signal transduction pathways, mutations in genes implicated in either signal recognition or propagation can induce the cell to behave inappropriately. Upon reaching the nucleus, signals from these proteins must communicate with transcription factors to elicit the changes in gene expression that can allow the cell to react to its new environment.
One class of transcription factors that it is thought to serve as the nuclear target of m any oncogenic signal transduction pathways is the activator protein 1 (AP-1) family (reviewed by Ransone and Verma, 1990; Angel and Karin, 1991) . This multigene group includes members of the Fos (c-fos, fosB, fra-l , and fra-2) and Jun (c-jun, junB, and junD) families. Members of the Fos family form heterodimers with Jun proteins and regulate transcription by binding DNA at AP-1 sites. These cis-acting regulatory elements are found in a variety of genes involved in cell proliferation, differentiation, and tumorigenesis. Oncogenic activation of several signal transduction pathways can result in increased AP-1 activity. For example, tumorigenic mutations in the proto-oncogene H-ras activate a family of mitogen-activated protein (MAP) kinases (JNKs/SAPKs) that phosphorylate Ju n to augment its transactivation potential (Pulverer et al., 1991; Binetruy et al., 1991) . Recently, an analogous class of Ras-responsive intracellular kinases has been described that seems to regulate Fos activity (Deng and Karin, 1994) . It is unclear from these in vitro studies, however, how elevated AP-l-dependent gene expression can contribute to cancer development in vivo.
A clue to the significance of AP-1 activity for cell transformation can be found in the history of fos and jun, as both genes were initially described as the transforming principles of oncogenic retroviruses (Curran et al., 1982; Maki et al., 1987) . Later studies using transgenic mice showed that stable expression of c-fos led to a dysregulation of bone growth eventually resulting in osteosarcomas and chondrosarcomas (Ruther et al., 1987 (Ruther et al., , 1989 . Transgenic mice expressing an oncogenic form ofjun developed fibrosarcomas at sites of wound healing (Schuh et al., 1990 ). These observations indicated that aberrant expression of AP-1 genes could affect mitogenic control and promote neoplastic transformation of specific tissues. Through the use of embryonic stem cell gene targeting technology, null mouse mutations of c-fos and c-jun have recently been generated (Johnson et al., 1992 (Johnson et al., , 1993 Wang et al., 1992; Hilberg et al., 1993) . While the c-jun knockout mutation is embryonic lethal, the c-fos null mouse is viable, though it displays a variety of tissuespecific anomalies. These defects include a severe form of osteopetrosis, a mild lymphopenia, delayed gametogenesis, and some behavioral abnormalities. In spite of these deficiencies, the availability of these mutant mice has allowed us to use them as tools to study the role of c-fos in cancer development in vivo. Our intention was to examine the unfolding of the neoplastic process in the absence of a critical component of the AP-1 family.
To address the relevance of c-fos for cancer development, we have used the classical model of multistep mouse skin carcinogenesis (reviewed by DiGiovanni, 1992; Hennings et al., 1993; Yuspa, 1994 -Szanto et al., 1989; Buchmann et al., 1991) . In this study, we have found that while c-fos does not seem to be necessary for normal epidermal differentiation or for the early proliferative steps of skin tumor formation, it is required for malignant tumor conversion. These results offer clear genetic evidence that an AP-1 factor is indispensable for the development of certain cancers.
Results

c-fos-Deficient Keratinocytes Form a Normal Epidermis
The skin is one of the few adult tissues in which c-fos expression has been reported to be constitutive (Fisher et al., 1991 ; Smeyne et al., 1992) . Coupled with the observation that functional AP-1 sites can be found in a variety of genes associated with epidermal development, this finding raised the possibility that the skin of c-fos null mice could display an aberrant pattern of differentiation. To uncover any intrinsic abnormalities in unperturbed c-losdeficient skin, we stained newborn epidermis with markers for specific stages of keratinocyte differentiation. Figure  1A shows double-labeled immunofluorescence staining for three markers: keratin 14 (K14), expressed in proliferating basal keratinocytes; keratin 1 (K1), induced in the differentiating spinous cells; and Ioricrin, a component of the cornified envelope expressed in the terminally differentiated cells of the granular layer. Comparison of the staining patterns for these and other epidermal differentiation markers failed to reveal any differences among mice of varying c-los genotype. Histological examination of newborn c-los-deficient skin showed that no obvious differc-los(+/+) c-fos(-/-) Figure 1 . ences exist in epidermal organization or cellularity ( Figure  1B ). Analogous results were obtained with thinner adult skin. Furthermore, when newborn mice were injected with bromodeoxyuridine to identify epidermal cells undergoing DNA replication, the number of proliferating cells was found to be similar in both genotypes (data not shown). These observations allowed us to conclude that, on the basis of keratinocyte growth rate or pattern of differentiation-dependent gene expression, the skin of c-los-deficient mice is indistinguishable from that of wild-type mice.
c-los Is Not Required for the Early Stages of Skin Carcinogenesis
To induce tumor formation in the skin of mice, we used a modified version of a traditional DMBA/TPA tumor induction protocol. Instead of using a chemical initiator, c-los mutant mice were bred with a transgenic strain (TG.AC) carrying a v-H-ras transgene that can act as a classical initiation event (Leder et al., 1990) . The existence of this transgenic strain enabled us to avoid the use of initiators that would have introduced undefined genetic mutations, potentially complicating the interpretation of the results. Even though the transgene is under the control of an embryonic globin promoter and thus is not normally active in the skin, expression of the transgene is induced in epidermal cells when they are prompted to proliferate either by application of tumor promoters or by a natural stimulus such as hair plucking Tennant, 1994a, 1994b) . Mice carrying the TG.AC transgene are very sensitive to a variety of tumor promoters; they rapidly develop large numbers of papillomas (Spalding et al., 1993) . Mice homozygous for the TG.AC transgene were mated with mice heterozygous for the c-los null mutation. Offspring carrying both mutations were identified and interbred to generate mice of all possible genotypes. The dorsal epidermis of these mice was then treated with the tumor promoter TPA twice a week for 5 weeks, according to standard promotion protocols for the TG.AC strain. Treated mice were monitored biweekly for the appearance of papillomas. As can be discerned from Figure 2 , c-losdeficient mice were able to develop papillomas, and they did so with equivalent kinetics to those of their wild-type and heterozygous littermates. Furthermore, the time to appearance of the first tumor and the number of papillomas per mouse were indistinguishable among genotypes. Because papillomas are very heterogenous and often tend to coalesce with other papillomas, size comparisons are difficult. Nevertheless, no obvious differences in tumor size could be observed among mice of differing genotypes. Table 1 summarizes benign tumor incidence rates. A small minority of v-H-ras transgenic mice in each group proved to be resistant to TPA treatment. This resistance did not correlate with c-los genotype and has previously been described for inbred FvB/N TG.AC mice. Two conclusions can be drawn from the data in Table 1 regarding the role of c-los in the early steps of mouse skin carcinogenesis. First, the absence of c-los cannot act as an initiating mutation because TPA-treated c-los null mice not carrying the v-H-ras transgene did not develop papillomas. Second, since c-los-deficient mice bearing the v-H-ras transgene developed papillomas in a normal manner, it is clear that in this model of carcinogenesis, this protooncogene is not necessary for promotion.
c-los-Deficient Papillomas Evolve into Horny, Elongated Tumors Characterized by Massive Hyperkeratinization
Although c-los-deficient papillomas initially displayed an identical external appearance to wild-type tumors, a striking change in morphology was noticed soon after the end of promotion. Within 4 weeks after TPA treatment was completed, the papillomas on all c-los null mice started to become very dry, elongated, and hyperkeratinized. This change in morphology was very apparent as the study advanced. Though some papilloma regression was observed in mice of all genotypes, the papillomas that persisted on wild-type and heterozygous mice remained vigorous and well vascularized. In contrast, mutant papillomas became desiccated and extremely hyperkeratinized and showed little external vascularization. Figure 3A shows a comparison of wild-type and c-los null papillomas soon after the end of promotion. While wild-type papillomas retained a similar morphology until the end of the study, c-los-deficient tumors acquired a rather horny appearance: they evolved into severely keratinized, grotesque projections. Examples of these older c-los-deficient tumors are shown in Figure 3C . Histopathology of wild-type and mutant papillomas revealed that c-los-deficient tumors indeed display a very dramatic hyperkeratinization, showing a remarkable increase in the terminally differentiated stratum comeum ( Figure 4 ). In addition, c-losdeficient papillomas seemed to present an abrupt transition between the basal layer and the stratum corneum, possibly suggesting a contraction of either the stratum spinosum or the granular layer. Tumors heterozygous for At 12 weeks of age, all mice were shaved and promotion treatment was started either with TPA or with solvent alone (acetone). Mice were monitored biweekly for the appearance of tumors. Papillomas per mouse and time to first tumor statistics are given as mean ± SD.
the c-fos null mutation appeared identical to wild-type papillomas: their morphology did not change, and they did not present an abnormal epidermal architecture.
To investigate whether these hyperkeratinized c-fosdeficient tumors showed an abnormal rate of regression, we compared the average number of papillomas per mouse at 9 weeks and at 23 weeks. Since TPA treatment was discontinued at the end of week 5, the majority of regressing papillomas should have disappeared by week 23. In wild-type mice, the mean number of papillomas per mouse decreased from 26 at week 9 to 10.5 at week 23 (a 60% reduction). Heterozygous mice showed a very similar decline, from 22.1 tumors per mouse at week 9 to 8.9 at week 23 (a 60% decrease). The mean number of papillomas per mouse in c-fos-deficient animals decreased from 23 at week 9 to 4.7 at week 23 (an 80% reduction). These data show that c-fos is not required for the persistence of papillomas. Whether papilloma regression rates are significantly affected by the c-fos null mutation is an issue that will require more study.
Papillomas Lacking c-fos Fail to Undergo Malignant Conversion
Wild-type mice began to develop malignant skin tumors around week 20, although most cases of malignant progression were noticed between weeks 25 and 30. Malignant lesions first appeared as ulcerated areas within a papilloma that grew rapidly. These malignant tumors were identified histologically as either squamous cell carcinomas or, more frequently, spindle cell tumors, in agreement with what has been described for the TG.AC strain (French et al., 1994) . By the end of the study (week 45), malignant progression had been observed in 4 of 7 (57%) surviving wild-type mice and in 7 of 17 (41%) heterozygous mice (Table 2 ). In contrast, no malignant skin tumors had been detected in 13 remaining c-fos null mice. A detailed pathological examination of all remaining c-fos-deficient papillomas at the end of the study failed to find any evidence of microscopic malignant progression. The decrease in the number of mice that were available at the later timepoint to assess progression is a reflection of the fact that the v-H-ras TG.AC transgene induces a variety of other tumors (e.g., hematopoietic malignancies) that necessitate the sacrifice of the affected animal. Nevertheless, the difference in progression rates of tumors with or without c-fos (57% and 41% versus 0%) is statistically significant (p < 0.0001) and allows us to conclude that c-fos is required for malignant progression of experimentally induced skin tumors. Wild-type and c-fos-deficient papillomas expressed similar levels of transgenic v-H-ras 1 month after the end of tumor promoter treatment ( Figure 5B) . Hence, the inability of c-fos-deficient papillomas to become malignant is not due to a reduced level of oncogenic H-ras expression. These final progression figures do not exclude the possibility of a heterozygous effect, although the finding that heterozygous papillomas behave like wild-type papillomas by all criteria examined argues against it.
Alterations in Gene Expression in c-fos Null Papillomas
To examine whether the lack of malignant progression of c-fos-deficient tumors correlated with specific changes in gene expression, we isolated RNA from pools of papillomas from wild-type and c-fos-deficient mice. Each pool consisted of five to six tumors taken 1 month after the end of TPA treatment. These RNAs were used to measure the degree of expression of certain AP-l-regulated genes in the papillomas. The genes encoding the tumor metalloproteases stromelysin and type I collagenase were of particular interest because studies using c-fos-deficient fibroblasts had shown that c-fos is required for the induction of these genes in response to mitogenic stimulation (Hu et al., 1994) . In addition, enhanced expression of these tumor metalloproteases has been associated with the progression of benign, encapsulated papillomas to malignant, invasive tumors (Matrisian et al., 1986; Liotta and StetlerStevenson, 1990) . While the stromelysin and type I collagenase mRNAs were detectable in the pools of wild-type tumors, they were virtually absent in RNA pools from c-fos-deficient papillomas ( Figures 5A and 5B) . The apparent lack of external vascularity of mutant tumors also prompted us to assess the level of expression of angiogenic factors in the papillomas. Of special interest was the pattern of expression of vascular endothelial growth factor (VEGF), for this protein may be the prime regulator of normal and tumor angiogenesis (Klagsbrun and Soker, 1993) . The VEGF gene was expressed in c-fos-deficient tumors, but the levels of VEGF mRNA measured in mutant papillomas were 5-to 10-fold lower than those found in RNA pools derived from wild-type papillomas ( Figure 5C ). The changes in keratin gene expression that take place during a protocol of skin carcinogenesis are well established and can often serve as markers of the degree of tumor progression. For example, papillomas with a high risk for malignant conversion frequently replace K1 expression with that of K13, a keratin whose expression is normally restricted to internal epithelia (Nischt et al., 1988; Gimenez-Conti et al., 1990) . Regions of premalignant papillomas that express K13 do not normally express KI. To monitor keratin gene expression in c-fos-deficient papillomas, we stained serial sections of tumors with antibodies prepared against an array of keratins. Surprisingly, K13 expression was ubiquitous in the suprabasal layers of c-fos-deficient papillomas. More significantly, though, while K1 and K13 expression was mutually exclusive in wild-type papillomas, these two keratins were, invariably coexpressed in the same cells in the mutant papillomas. c-fos-deficient papillomas examined ( Figure 6 ). Since these type 1 and type 2 keratins do not normally form filament pairs, coexpression of K! and K13 in the same cells could result in the formation of an irregular intermediate filament network that may contribute to the unusual amount of cornification displayed by mutant papillomas.
In contrast with wild-type cornified envelopes, which disassociate when tumors are boiled, large clumps of tightly connected c-fos-deficient envelopes endured even after the mutant papillomas were boiled for 5 hr in 2% SDS (data not shown). The considerable durability of c-fos-deficient cornified envelopes may reflect interesting underlying biochemical differences, such as covalent modifications in the structure of the envelopes.
c-fos-Deficient Keratinocytes Expressing v-H-ras Do Not Form Tumors When Grafted onto Nude Mice
The development of a malignant neoplasm is a process that involves an intense interaction between tumor cells and normal neighboring cells (reviewed by Paweletz and Boxberger, 1994) . The inability of c-fos-deficient papillomas to progress into malignant tumors could be due to an intrinsic defect in the v-H-ras-expressing keratinocytes that form the epidermal component of the papillomas. AI- Serial sections of tumors (obtainecl 2.5 months after the start of the study) were stained with antibodies against K1 (bottom) and K13 (top) and photographed at the same magnification (32x). Note the coexpression of K1 and K13 in c-fos-deficient tumors.
K1 growth. To establish whether c-fos-deficient keratinocytes display a cell-autonomous defect that prevents them from giving rise to malignant tumors, we tested the ability of v-H-ras-expressing mutant keratinocytes to form tumors when grafted onto the back of wild-type hosts (Hoop et al., 1986). Primary keratinocytes derived from c-fos-deficient,
heterozygous, and wild-type mice were infected with a helper-free retrovirus, a variant Harvey murine sarcoma virus (Ha-MSV), expressing an oncogenic form of H-ras (Hoop et al., 1986) , were mixed with wild-type dermal fibroblasts, and were grafted onto the back of athymic nude mice. Grafted Ha-MSV-infected wild-type keratinocytes gave rise to large papillomas. In contrast, grafts of infected c-fos-deficient keratinocytes did not produce significant tumors. Rather, v-H-ras-expressing cells lacking c-fos generated a normal epidermis that was hyperplastic in some cases. Interestingly, grafts of keratinocytes heterozygous for the c-fos null mutation gave rise to small tumors of variable size that on average were approximately 35% the size of their wild-type counterparts. While there was some variation in absolute tumor volume values, the same trend was observed in three independent experiments: v-H-rasexpressing keratinocytes homozygous for the c-fos null mutation failed to produce tumors (n = 8), heterozygous cells generated small, fragmented papillomas (n = 12), and wild-type keratinocytes gave rise to large tumors (n = 14). Mice from a representative experiment are shown in Figure 7A . The presence of black pigment in mice with grafts of c.fos-deficient keratinocytes indicates that the graft was successful. Figure 7B displays the evolution of tumor volume as a function of time for that same experiment. Mice with c-fos-deficient grafts failed to develop tumors, even when monitored for 3 months (6 weeks beyond the normal observation period). Since tumor formation in this system is dependent upon oncogenic H-ras expression, the levels of mutant Has protein in keratinocytes used for grafting were examined. All Ha-MSVinfected keratinocytes, regardless of genotype, expressed equivalent levels of exogenous Has in vitro as well as in vivo (data not shown). The growth rate in vitro of all v-H-rasexpressing keratinocytes was similar, regardless of c-fos genotype (data not shown). Furthermore, implanted c-fos null keratinocytes coinfected with Ha-MSV and a v-fos retrovirus generated dysplastic tumors indistinguishable from those produced by similarly infected wild-type cells, confirming that a fos-dependent function is responsible for the deficiency in tumor formation of mutant cells (data not shown). These transplantation experiments illustrate that v-H-ras-expressing keratinocytes derived from c-fos null animals appear to have a cell-autonomous defect that hampers tumorigenesis.
Discussion
Tumorigenesis is a complex process that requires alterations in many genes involved in the regulation of cell growth. Many of these genes function outside of the nucleus of the cell and must ultimately exert their effects by communicating with transcription factors. The AP-1 family is believed to be one of the nuclear targets of several signal transduction pathways, in particular the Has-MAP kinase pathway (reviewed by Hill and Treisman, 1995) . Because these pathways are frequently dysregulated by activated oncogenes, it is of considerable interest to determine whether AP-1 factors are actually necessary for cancer development. We have used the well-characterized model of multistep mouse skin carcinogenesis to examine the unfolding of the neoplastic process in the absence of c-fos, an important member of the AP-1 family. Our results demonstrate that c-fos is required for the development of malignant skin tumors.
The Role of c-fos in Initiation and in Promotion
To test the role of c-los in the various steps of skin carcinogenesis, we mated mice heterozygous for the c-fos null mutation with a transgenic strain carrying a v-H-ras transgene that can substitute for a chemical initiation step. Even though mutations in H-ras are very common during initiation in DMBA/TPA protocols, skin tumors induced with other carcinogens frequently do not bear H-ras mutations (Bremner et al., 1994) . This observation suggests that mutations in other unspecified genes can also serve as initiating events. To examine whether c-fos could be one of these unidentified genes, we treated c-fos null mice not carrying the v-H-ras transgene with the tumor promoter TPA. The absence of papilloma formation established that a c-fos null mutation cannot serve as an initiation event.
Mutant mice bearing the v-H-ras transgene were able to develop papillomas normally upon TPA treatment. That c-fos-deficient papillomas appeared with standard kinetics and in comparable numbers to wild-type tumors shows that, under these experimental conditions, c-fos is not required for benign tumor formation. Because c-fos is an immediate-early gene whose expression is often used as a marker of cellular proliferation, it may have been anticipated that the main contribution of c-fos to oncogenesis would be either to accelerate the rate of cell division or to prevent exit from the cell cycle. Clearly, this does not seem to be the case in this study. It is possible that during promotion, TPA induces the expression of other genes that can functionally complement the absence of c-fos. Nonetheless, since in the vast majority of experimental carcinogenesis protocols, TPA promotion is continued for many weeks, the real relevance, if any, of c-fos for tumor promotion would also be concealed under those circumstances. Thus, we can conclude that, while it may be important, c-fos is not essential for tumor promotion brought about by TPA treatment.
Abnormalities of Epidermal Differentiation in c-fos-Deficient Papillomas
Although initially identical to wild-type papillomas, shortly after the end of TPA treatment, c-los-deficient tumors began to manifest some clear differences. Over time, c-fosdeficient papillomas are characterized by a grotesque hyperkeratinization. Mutant papillomas evolve into horny projections covered by a crust of keratin that can grow as long as 2-3 cm. The development of such elongated, hyperkeratinized papillomas (with the great frequency found here) seems to be unique for a carcinogenesis proto-col. It was surprising to find universal K13 expression in these apparently benign tumors, for K13 induction has heretofore been considered a useful diagnostic of premalignant progression. It is important to note that these c-fosmediated differences in epidermal differentiation are only apparent within the context of carcinogenesis, for no differentiation abnormalities were detected in untreated c-fosdeficient epidermis. Hence, it is conceivable that the observed differences are contingent on the expression of a mutant H-Ras protein. It is also possible that the expression of the various members of the AP-1 family may be abnormally regulated during tumorigenesis. Given the large number of AP-1 sites that have been identified in epidermal differentiation genes, disorderly expression of other AP-1 members in the absence of c-fos may have profound effects. Using immunohistochemistry, we have been unable to recognize significant differences in the expression pattern of AP-1 genes in wild-type and mutant papillomas (data not shown). However, since the activity of AP-1 proteins can be regulated by reversible phosphorylation, it is possible that differences may exist in AP-1-dependent gene expression that are not reflected in an unusual pattern of AP-1 family protein expression.
The Role of c-los in Papilloma Survival and Malignant Progression
In contrast with wild-type and heterozygous tumors, not a single c-fos-deficient papilloma progressed to malignancy by the end of the study. Several explanations can potentially account for this observation. It is well established that c-fos controls the expression of a variety of genes that are up-regulated during malignant progression, including those encoding the tumor metalloproteases stromelysin and type I collagenase (Kerr et al., 1988; Schonthal et al., 1988; Hennigan et al., 1994) . The tumor metalloproteases are a group of secreted enzymes that can degrade the extracellular matrix, thereby facilitating tumor growth, invasion, and metastasis (reviewed by Liotta and StetlerStevenson, 1990) . Increased metalloprotease expression has been associated with malignant progression in many models of in vivo cancer development (reviewed by McDonnell and Matrisian, 1990) . Given that the transcripts for stromelysin and type I collagenase were undetectable in RNA obtained from pools of mutant papillomas, it is likely that a protease insufficiency may contribute to the lack of malignant behavior of c-fos-deficient tumors.
The sparse external vascularity displayed by c-fosdeficient papillomas suggests a second possible factor for the benign nature of c-fos-deficient tumors. At a molecular level, the formation of new blood vessels is a process remarkably similar to tumor invasion and metastasis, for angiogenesis also requires cells to traverse normal tissue boundaries and degrade the basement membrane of the tissue to be vascularized (reviewed by Liotta et al., 1991) . c-fos could be mediating tumor angiogenesis not only through its control of the proteases that are critical for these processes, but also by modulating the expression of the growth factors that induce neovascularization, such as VEGF. Indeed, we have observed that the level of VEGF mRNA is significantly reduced in RNA extracted from pools of c-fos-deficient tumors. Finally, it is conceivable that the abnormal pattern of differentiation of c-fosdeficient papillomas may interfere or be incompatible with ordinary tumor progression.
Diminished expression of tumor metalloproteases and angiogenic factors may also contribute to the inability of grafted v-H-ras-expressing c-fos-deficient keratinocytes to generate papillomas. The development of an established graft/tumor involves complex fibroblast-keratinocyte interactions that must ultimately result in, among other things, the creation of a new blood vessel network to support the growth of the graft (Smola et al., 1993; Borchers et al., 1994) . In the multistep carcinogenesis system, the requirement for angiogenesis may be less stringent, at least for the early stages of tumor development. Since tumors are induced in skin that is already vascularized, initially neoplastic cells need only to expand the existing capillary network, not to establish a completely new one. It is also possible that chemical treatment in the multistep carcinogenesis system induces the expression of genes that allow papilloma formation in the absence of c-fos. Many genes, including those encoding the tumor metalloproteases stromelysin and type I collagenase, are known to be expressed in response to tumor promoter stimulation; c-fos-deficient fibroblasts can express a limited amount of these proteases when stimulated with TPA (Krieg et al., 1988; Hu et al., 1994) . The defect in tumor development observed in the grafting system could also be due to an autocrine overproduction of a growth-inhibiting molecule (e.g., transforming growth factor 13) by c-fosdeficient cells. Alternatively, v-H-ras-expressing mutant cells may be more sensitive to constraining signals emanating from the wild-type cells that constitute the stromal component cf the implant. The experimental flexibility of the skin grafting system should permit the reintroduction of proteases and angiogenic factors to test whether the cell-autonomous defect in tumorigenesis of c-fcs-deficient keratinocytes is linked to the expression of these genes.
Although the specific details of why c-fos-deficient papillomas fail to progress to malignancy are yet to be elucidated, these findings might provide a molecular mechanism for the observation that treatment with retinoids and glucocorticoids can prevent malignant progression of mouse skin tumors, as well as the occurrence of secondary tumors in carcinomas of the head and neck in humans (Hong et al., 1990; Strawhecker and Pelling, 1992; De Luca et al., 1993) . Both, the retinoic acid receptors and the glucocorticoid receptor are known to antagonize AP-1-dependent transcription directly (Schule et al., 1990; Kerppola et al., 1993) . Thus, it is possible that the inhibitory action of these hormones on AP-1 activity is at least partially responsible for their antitumorigenic effects.
Relevance to Other Neoplastic Processes
An important question is whether these findings will be meaningful for tissues other than the epidermis. We have indirectly addressed this issue by monitoring the frequency of the spontaneous tumors induced by the v-H-ras TG.AC transgene in c-fos-deficient mice. We have found that while c-fos is dispensable for the genesis of some nonsolid neoplasms, it appears to be critical for the development of certain solid tumors, such as odontogenic fibrosarcomas (unpublished data). Moreover, a variety of other human and rodent tumors are known to overexpress c-fos (e.g., Honoki et al., 1992; Urabe et al., 1992) . One of these tumors is human squamous cell carcinoma of the lung (Volm et al., 1992; Wodrich and Volm, 1993) . Because the development of this cancer naturally requires repeated applications of a tumor promoter (e.g., tobacco smoke), many consider this human cancer the most accurate reflection of the mouse skin model. Another clinically relevant tumor in which c-fos overexpression is associated with' malignant progression is human breast cancer (Biunno et al., 1988; Walker and Cowl, 1991) .
Our findings highlight the significance of c-fos for full neoplastic development. Since malignant progression is the most critical step in terms of host survival, the identification of agene central to this process represents a promising step toward the therapeutic prevention of neoplastic disease. Furthermore, because c-fos is not required for the viability of the whole organism, it may represent an attractive target for pharmacological intervention.
Experimental Procedures
Animals c.fos-deficient mice were generated as previously described (Johnson et al., 1992) . Mice heterozygous for the c-fos null mutation (50% 129/ SvJ; 50% C57BU6J) were mated with FvB/N mice homozygous for the TG.AC transgene obtained from Charles River Laboratories. Offspring carrying both the TG.AC transgene and the c-fos mutation were identified and interbred. Their progeny was typed for both mutations and divided into the groups shown in Table 1 . At 12 weeks of age, mice were shaved, and their dorsal epidermis was treated with either 5 ~g of TPA (Sigma) dissolved in 100 pJ of acetone or acetone alone. To normalize for their reduced size (and hence smaller dorsal surface area), c-fos-deficient mice received 55% of the wild-type dose of promoter. This dose of TPA resulted in a similar papilloma yield in wild-type and mutant mice (see Table 1 ). Treatment was applied twice a week for 5 weeks. Male mice were caged individually to prevent wound-induced tumors. All mice were examined at least once a week for a period of 45 weeks.
Histology and Immunohistochemistry
For pathological analysis, complete autopsies were performed and tissues were fixed in Optifix. Tumors were not removed from mice under observation. For fluorescent immunohistochemistry, neonatal skin was frozen in OCT (Miles Incorporated). Double-labeled indirect immunofluorescence was performed as described by Nischt et al. (1988) . Antisera against mouse keratins and Ioricrin are characterized by Yuspa et al. (1989) and Mehrel et al. (1990) .
Cell Culture and Retroviral Infections
Breeding pairs of animals heterozygous for the c-fos null mutation were monitored daily for the appearance of offspring. Neonatal mice were genotyped by PCR (Johnson et al., 1992) . After sacrifice, animals were kept on ice until typing results became available (24 hr). The skin from selected mice was removed, and primary keratinocytes were prepared as described by Hennings et al. (1980) . Dermal fibroblasts from the same c-los wild-type mice used to derive keratinocytes to be grafted were cultured separately for 1 week (Yuspa et al., 1976) . Primary keratinocytes were infected 3 days after plating at a multiplicity of 1 with a replication-defective variant of Ha-MSV devoid of helper virus and containing the v-H-ras gene (Roop et al., 1986) . After 5 days, keratinocytes and fibroblasts were combined and grafted. Wild-type fibroblasts were used for grafting keratinocytes of all three genotypes. Successful Ha-MSV infection and p21 H,Ras expression were monitored by analyzing total protein extracts of infected keratinocytes by Western blot and by immunohistochemistry on grafts, using an antibody against p21 H-Ras (Transduction Laboratories).
In Vivo Grafting
Combined cell pellets were transplanted onto 8-to 12-week-old athymic nude mice as described by Strickland et al. (1993) . The volume of tumors was measured on a weekly basis, starting 2 weeks after grafting. Mice were sacrificed after 6 weeks of observation, unless otherwise noted.
Statistical Analysis
Statistical work was performed by the Division of Biostatistics at the Dana-Farber Cancer Institute. The associations between c-los genotype and the incidence of epidermal tumors were analyzed with log linear models using GLIM (GLIM4, 1992 Royal Statistical Society, London), evaluating the association both assuming and not assuming and ordering to the genotype (+/+ > +/-> -/-); p values of <0.05 were considered significant.
